rodent studies) to neuroscience. A door has been opened by Evrard et al. (2012), but much exciting work remains to be done.
N-methyl-D-aspartate (NMDA) receptor activation can be neuroprotective or neurotoxic depending on receptor location. In this issue of Neuron, Martel et al. (2012) demonstrate that the C-terminal of NMDA receptor subunits also contributes critically to excitotoxicity. NMDA receptor subunits containing the GluN2B C-terminal are more lethal than those containing the GluN2A tails, regardless of location.
Is the location of N-methyl-D-aspartate receptors (NMDARs) at synaptic or extrasynaptic sites the only, or even the primary, determinant of neuroprotective or neurotoxic effects of glutamate? While we thought this question had been settled, at least partially (Levine et al., 2010; Milnerwood et al., 2010; Okamoto et al., 2009) , new work from the laboratory that raised into prominence the differential role of synaptic and extrasynaptic NMDARs and gave us a better understanding of the intracellular cascades that lead to excitotoxicity (Hardingham et al., 2002) now demonstrates that we were missing part of the equation, a little but important C-tail. In effect, the C-terminal domain (CTD) of the NMDAR subunit appears to play a critical role in the function of the receptor.
In an elegant study published in this issue of Neuron, Martel et al. (2012) report that the activation of proapoptotic cascades is determined not just by the location of the NMDAR, but also by the identity of the CTD. As pharmacological approaches commonly used to differentiate the two subunits are limited at best, the authors used genetic manipulations to engender chimeric receptors in which only the CTD from GluN2A and GluN2B receptor subunits is C-terminal replaced (CTR). Why focus on the CTD? It has been shown that the CTD of NMDAR subunits is the primary area of sequence divergence, and it is the site that primarily binds scaffolding proteins, providing a strong rationale for examining its role in excitotoxicity.
In the first series of experiments, expression of chimeric GluN2B . Similarly, neurons expressing GluN2A 2B(CTR) were more susceptible to cell death than neurons expressing GluN2A WT (Figure 1 ).
Using a different approach, a knockin mouse was generated in which the protein-coding region of the C-terminal exon of the GluN2B subunit was exchanged for that of the GluN2A subunit, named Martel et al. (2012) found that GluN2B +/+ neurons coupled more strongly to NMDA-induced NO production and concluded that stronger CTD 2B coupling to PSD-95, NO production, and nNOS-dependent CREB inactivation leads to enhanced vulnerability to excitotoxic insults. Finally, the basis for the stronger association of PSD-95 with GluN2B WT compared to GluN2B 2A(CTR) was explored. An internal region of the CTD 2B (1086-1157), when deleted, resulted in a decrease in PSD-95 association, whereas overexpression of this region led to reduced NMDA-induced cell death. This region thus could be implicated in NMDAR signaling leading to cell death. The idea that GluN2A and GluN2B subunits play different roles in diverse processes such as synaptic plasticity, intracellular signaling, and excitotoxicity has often been entertained. In the case of synaptic plasticity, experimental evidence is not conclusive, and it appears that both subunits are necessary (Mü ller et al., 2009). However, there is evidence that GluN2A and GluN2B subunits affect a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor trafficking in opposite ways, with GluN2A promoting and GluN2B inhibiting surface expression of GluA1 subunits.
In the realm of excitotoxicity, it was previously demonstrated that activation of GluN2B-containing NMDA receptors, at either synaptic or extrasynaptic sites, leads to excitotoxicity, whereas activation of either synaptic or extrasynaptic GluN2A-contaning NMDARs promotes neuronal survival and is neuroprotective (Liu et al., 2007) . In this study, administration of glycine alone or in the presence of a GluN2B antagonist attenuated ischemic brain damage. Understanding the mechanisms of NMDAR-mediated excitotoxicity is paramount to the development of better neuroprotective tools in acute and chronic conditions. While great strides had been made, many of them by Hardingham's group, the intimate mechanisms of excitotoxicity had been missing. Although the increased presence of GluN2B subunits in extrasynaptic locations is still a matter of debate, the role of these subunits in NMDAR-mediated toxicity is well supported by experimental evidence.
Huntington's disease (HD) is one good example in which the present findings can open new venues for therapies. Recent studies (Milnerwood et al., 2010; Okamoto et al., 2009) , partly promoted by Hardingham's previous work, have demonstrated enhanced extrasynaptic NMDAR-mediated activity in HD mouse models and the effectiveness of memantine (an NMDAR antagonist used as a more selective extrasynaptic receptor blocker) for the treatment of some HD symptoms. Lynn Raymond's laboratory in Vancouver has demonstrated the important role that the GluN2B subunit plays in striatal cell death in HD. Expression of mutant huntingtin (htt) has been hypothesized to alter striatal NMDAR signaling (Raymond et al., 2011 ). In the Excess glutamate can be excitotoxic via NMDARs. However, the extent of cell death depends in part on the CTD of NMDAR subunits. Swapping the CTD from GluN2A for GluN2B produces more cell death. Conversely, swapping the CTD from GluN2B for GluN2A reduces cell death. Similarly, cells from genetically modified knockin mice, in which the CTD from GluN2B is replaced by the CTD of GluN2A, are less vulnerable than cells from GluN2B +/+ mice, due in part to increased phosphorylation of CREB. In contrast, CTD 2B displays stronger coupling to the PSD-95/nNOS pathway, which suppresses CREB activation. This indicates that the GluN2B subunit, regardless of location at synaptic or extrasynaptic sites, is more lethal than the GluN2A subunit.
early stages of the disease, studies in HD genetic mouse models have shown increased NMDAR-induced currents (Starling et al., 2005) . Importantly, this increase appears to be mediated by NMDAR-containing GluN2B subunits, as enhanced currents and toxicity in cultured neurons and acute slices are abolished by ifenprodil or memantine (Kaufman et al., 2012) . Thus, experimental evidence supports the idea that mutant htt enhances cell death by modulating GluN2B subunits. In agreement, dramatic exacerbation of striatal neuronal loss was reported when HD knockin mice were crossed with GluN2B-overexpressing mice (Heng et al., 2009) . Does the presence and relative abundance of GluNR2B subunits make neurons more vulnerable? A recent study showed that mediumsized spiny neurons (MSNs) of the indirect striatal output pathway, i.e., the neurons that are believed to be more affected in the early stages of HD, express more functional GluN2B-containing NMDARs (Jocoy et al., 2011) . In contrast, MSNs of the direct pathway appear to express relatively greater levels of GluN2A subunits and are less affected.
While these studies are indicative of contrasting roles of NMDAR subunits, it was not until the present work by Martel et al. (2012) that the precise locus and mechanisms have been unraveled. Based on their findings, the GluN2B/PSD-95/ nNOS axis represents an attractive target for therapeutic intervention. Indeed, as the authors indicate, results from a series of studies demonstrating antiexcitotoxic effects of TAT-NR2B9c, PSD-95 knockdown, or disruption of the PSD-95-nNOS interface can now be explained. In addition, the translational potential is great and is supported by recent evidence that administration of TAT-NR2Bc, even hours after stroke, can prevent neuronal damage and neurological deficits (Cook et al., 2012) . While the role of NO in disease processes such as HD remains to be established, neuroprotective or neurotoxic effects can occur depending on a number of factors (Deckel, 2001) .
Although the new findings of Martel et al. (2012) are revealing, more studies will be necessary to understand how identity and location of GluN2 type subunits at synaptic and extrasynaptic sites contribute to excitotoxicity. In particular, visualization of NMDAR surface mobility in and out of the synapse in native conditions will be extremely useful. For example, using single-particle and singlemolecule tracking approaches, NMDAR mobility has been shown to depend on the identity of GluN2-type subunits, as NMDARs containing GluN2B subunits are less stable than those containing GluN2A subunits (Groc et al., 2006) . In conclusion, the present contribution will certainly become another classic in the field of NMDAR-mediated neurotoxicity, with far-reaching scientific and clinical implications. As the GluN2 subunit saga moves on, the ''tail'' of 2B or not 2B remains an important component of the question.
